R&D Pipeline

R&D Pipeline (In-House)

As of May 2022

Product Name
/ Generic Name
/ Development Code
Expected Indications Category Development Stage Development Classification

TAVNEOS® Capsules
/ Avacopan

Microscopic polyangiitis Granulomatosis with polyangiitis Selective C5a receptor antagonist Preparation for launch In-licensed /
Vifor Fresenius Medical Care Renal Pharma (Switzerland)
CAROGRA® Tablets
/ Carotegrast Methyl
Ulcerative colitis Alpha 4 integrin receptor antagonist Preparation for launch In-licensed /
Co-development with EA Pharma (Japan)
Rovatirelin
/ KPS-0373
Spinocerebellar ataxia TRH receptor agonist NDA In-licensed /
Shionogi (Japan)
Fostamatinib
/ R788
Chronic idiopathic thrombocytopenic purpura Tyrosine kinase inhibitor NDA In-licensed /
Rigel Pharmaceuticals (U.S.)
Difelikefalin
/ MR13A9
Uremic pruritus in dialysis patients Kappa opioid receptor agonist Phase III In-licensed /
Co-development with Maruishi Pharmaceutical (Japan)
Primary endpoint achieved
CG0070 Non-muscle-invasive bladder cancer Oncolytic Viral Therapy Phase III In-licensed /
CG Oncology (U.S.)
Linzagolix
/ KLH-2109
Endometriosis GnRH receptor antagonist Phase II Kissei
KDT-3594 Parkinson's disease Dopamine receptor agonist Phase II Kissei
KSP-0243 Inflammatory bowel disease Phase I Kissei



R&D Pipeline (Out-Licensing)

As of May 2022

Generic Name
/ Development Code
Expected Indications Category Countries & Regions Development Company Development Stage
Linzagolix Uterine fibroids GnRH receptor antagonist EU, US ObsEva SA (Switzerland) NDA
Endometriosis EU, US Phase III
Uterine fibroids, Endometriosis China Bio Genuine (China) Preparation for Clinical Trial
Silodosin Dysuria associated with benign prostatic hyperplasia Alpha 1A adrenergic receptor antagonist Vietnam, etc. Eisai (Japan) NDA
KDT-3594 Parkinson's disease Dopamine receptor agonist China, etc. AffaMed (China) Phase II
Bedoradrine Acute exacerbation of asthma Beta 2 adrenergic receptor agonist US MediciNova (U.S.) Phase II
Fostamatinib Chronic idiopathic thrombocytopenic purpura Tyrosine kinase inhibitor Korea JW Pharmaceutical (Korea) NDA preparation
China, etc. Inmagene Biopharmaceuticals (China) Preparation for Clinical Trial